67 related articles for article (PubMed ID: 3278833)
21. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.
Doi Y; Murray GL; Peleg AY
Semin Respir Crit Care Med; 2015 Feb; 36(1):85-98. PubMed ID: 25643273
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.
Penwell WF; Shapiro AB; Giacobbe RA; Gu RF; Gao N; Thresher J; McLaughlin RE; Huband MD; DeJonge BL; Ehmann DE; Miller AA
Antimicrob Agents Chemother; 2015 Mar; 59(3):1680-9. PubMed ID: 25561334
[TBL] [Abstract][Full Text] [Related]
23. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.
Viehman JA; Nguyen MH; Doi Y
Drugs; 2014 Aug; 74(12):1315-33. PubMed ID: 25091170
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
Soto E; Shoji S; Muto C; Tomono Y; Marshall S
Br J Clin Pharmacol; 2014 Mar; 77(3):509-21. PubMed ID: 24102758
[TBL] [Abstract][Full Text] [Related]
25. Acinetobacter baumannii: emergence of a successful pathogen.
Peleg AY; Seifert H; Paterson DL
Clin Microbiol Rev; 2008 Jul; 21(3):538-82. PubMed ID: 18625687
[TBL] [Abstract][Full Text] [Related]
26. Serum and blister fluid pharmacokinetics and bactericidal activities of ampicillin-sulbactam, cefotetan, cefoxitin, ceftizoxime, and ticarcillin-clavulanate.
Jaresko GS; Barriere SL; Johnson BL
Antimicrob Agents Chemother; 1992 Oct; 36(10):2233-8. PubMed ID: 1444304
[TBL] [Abstract][Full Text] [Related]
27. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
28. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections.
Betrosian AP; Douzinas EE
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1099-112. PubMed ID: 19621991
[TBL] [Abstract][Full Text] [Related]
29. [A combination of ampicillin and sulbactam: effect on aerobic and anaerobic gram-negative bacteria].
González C; García A; Urrea R; del Solar E; Bello H; Zemelman R
Rev Med Chil; 1990 May; 118(5):548-54. PubMed ID: 2293275
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of beta-lactamases by sulbactam and enhanced clinical activity due to target-site binding of the combination of sulbactam and ampicillin.
Yokota T
APMIS Suppl; 1989; 5():9-16. PubMed ID: 2786726
[TBL] [Abstract][Full Text] [Related]
31. Sulbactam: a beta-lactamase inhibitor.
Noguchi JK; Gill MA
Clin Pharm; 1988 Jan; 7(1):37-51. PubMed ID: 3278833
[TBL] [Abstract][Full Text] [Related]
32. Worldwide clinical experience with sultamicillin.
Pitts NE; Gilbert GS; Knirsch AK; Noguchi Y
APMIS Suppl; 1989; 5():23-34. PubMed ID: 2660868
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
